{"nctId":"NCT01052844","briefTitle":"Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy","startDateStruct":{"date":"2009-01"},"conditions":["Vomiting","Cisplatin Adverse Reaction"],"count":80,"armGroups":[{"label":"Control group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Gabapentin","type":"EXPERIMENTAL","interventionNames":["Drug: Gabapentin"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Gabapentin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* First course of chemotherapy ( cisplatin or doxorubicin at a dose of at least 50mg per square meter)\n* Written informed consent must be obtained before initiating the protocol procedures\n\nExclusion Criteria:\n\n* ECOG 3\n* Nausea and vomiting within the past 1 day\n* Gastrointestinal obstruction\n* Concurrent use of opioid\n* Patients with brain metastases\n* History of allergic or other adverse reaction to gabapentin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Complete Response During Chemotherapy Course 1","description":"The CR was defined as no emetic episodes and no nausea episodes from day 1 to day 5 (0-120h)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1","description":"Complete response during delayed-onset phase was defined as the absence of any episode of nausea or vomiting and no use of rescue medication when occurring during the period from days 2 through 5 after chemotherapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Xerostomia","Sleepiness","Dizziness","Constipation","Heartburn"]}}}